Novartis hires Dana-Farber's Bradner; Glaxo vacates, sells NC lab;

Novartis

@FiercePharma: Toxin from sea algae impacts memory, behavior in California sea lions: Study. More from FierceAnimalHealth | Follow @FiercePharma

@EricPFierce: Mylan wants some payback for plants it bought from Strides that have been cited by FDA. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: AstraZeneca shrugs off pharma's emerging markets slowdown, but Lilly's suffering. Article | Follow @CarlyHFierce

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> Novartis ($NVS) has brought on James Bradner of Harvard's Dana-Farber Cancer Institute to head its Institutes for Biomedical Research. Report

> GlaxoSmithKline ($GSK) has vacated a lab building at Imperial Center in Durham and sold the property to a real estate investor for $10 million. Report

> Massachusetts has approved a tax break tallying $7 million-plus to offer Alnylam ($ALNY) if it builds a $100 million manufacturing plant there. Report

> Novo Nordisk ($NVO) says its Phase IIIa trial of diabetes hopeful semaglutide has hit its objective. Report

> German airline Lufthansa is playing down rumors that it could get a new chairman after Merck KGaA CEO Karl-Ludwig Kley said he would accept the job if he were offered it. Report

Medical Device News

@FierceMedDev: NYU researchers roll out ResearchKit app as part of concussion-monitoring study. Article | Follow @FierceMedDev

@EmilyWFierce: In this week's Dx Digest, $ILMN makes waves in China and $LH buys a women's health lab. More | Follow @EmilyWFierce

> VA signs onto ReWalk Robotics' exoskeleton device for paralyzed veterans. Report

> Australian teams aims to create dialysis-like blood filtration system to treat cancer. Article

> Startup touts first-in-man study of its sensor for cardiac ablation catheters in hopes of partnership. Story

Biotech News

@FierceBiotech: Biotech bad boy Martin Shkreli faces a new set of angry foes: federal prosecutors. News | Follow @FierceBiotech

@JohnCFierce: Gilead steps in to replace AbbVie with $2B Galapagos collaboration. News | Follow @JohnCFierce

@DamianFierce: it is with solemn humility that I now accept the mantle of Biotech's Bad Boy. thank you. | Follow @DamianFierce

> AstraZeneca bets $7B on Acerta's potential blockbuster cancer treatment. Report

> Kahr Medical leans on Korean VCs to raise $12M for oncology R&D. Story

> University of California commits $250M for a new tech venture fund for biotech, more. Article

CRO News

> PPD reportedly on the block for $8B. Report

> Recipharm signs on to manufacture an in-development cancer drug, investing in a Swedish biotech. Article

> On the rebound, AMRI trades $52M for a testing firm. News

Pharma Manufacturing News

> AstraZeneca shifts supply chain strategy from air to sea freight shipments. Report

> GSK opens Australia pilot plant to test blow-fill-seal technology on vaccines. Article

> WuXi and PRA canceling joint venture in China. Item

> Deadline looms to meet new label and insert requirements in Taiwan. More

> WuXi to sell AstraZeneca China's largest biologics plant for $100M. News

Pharma Asia News

> Indian healthcare IPOs raise $300M. Item

> Don't count India out yet in biosimilars race, Quintiles exec says. More

> YiChang IPO joins other drug companies in tough IPO market. Report

> Taiwan sets June 2016 deadline on new packaging, insert rules. Story

> WuXi venture unit raises $290M for 'find in U.S., build in China' venture fund. Article

And Finally... China's drug regulator is set to strengthen oversight of clinical trials of new drugs. More

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.